(ABLD) AbL Diagnostics - Ratings and Ratios
Exchange: PA •
Country: France •
Currency: EUR •
Type: Common Stock •
ISIN: FR001400AHX6
Description: ABLD AbL Diagnostics
ABL Diagnostics Société anonyme provides proprietary molecular biology assays and end-to-end solutions to be used for molecular detection by polymerase chain reaction (PCR) and through DNA sequencing in France and internationally. It offers genotyping through NGS and sanger sequencing for human immunodeficiency virus, SARS CoV-2, hepatitis-C virus, mycobacterium tuberculosis, and 16S RNA; ultragene assays for viral detection of SARS CoV-2, dengue, and Zika virus; microbiological specimen transport and collection kits, which include RNA and saliva preservation, wastewater collection, and surface collection kits, as well as inactivation and preservation solution; and instrument and consumables, such as DNA/RNA extraction system, real-time PCR system, liquid handling robot, NGS library preparation system, and sanger sequencing reagents. The company also provides digital solutions comprising analysis software, data hosting, lab automation, Nadis, and SeqHepB. It sells its products directly, as well as through a network of distributors to academic clinical pathology labs, private reference labs, and researchers. The company was formerly known as Etablissements Fauvet Girel and changed its name to ABL Diagnostics Société anonyme in April 2022. The company is based in Woippy, France. ABL Diagnostics Société anonyme is a subsidiary of Advanced Biological Laboratories (ABL) S.A., Web URL: https://www.abldiagnostics.com
Additional Sources for ABLD Stock
ABLD Stock Overview
Market Cap in USD | 103m |
Sector | Healthcare |
Industry | Health Information Services |
GiC Sub-Industry | Health Care Technology |
IPO / Inception |
ABLD Stock Ratings
Growth Rating | 30.0 |
Fundamental | - |
Dividend Rating | 1.0 |
Rel. Strength | 111 |
Analysts | - |
Fair Price Momentum | 5.68 EUR |
Fair Price DCF | - |
ABLD Dividends
Dividend Yield 12m | 1.21% |
Yield on Cost 5y | 1.17% |
Annual Growth 5y | % |
Payout Consistency | 1.0% |
Payout Ratio | % |
ABLD Growth Ratios
Growth Correlation 3m | -60.7% |
Growth Correlation 12m | 79.3% |
Growth Correlation 5y | 35% |
CAGR 5y | 12.32% |
CAGR/Max DD 5y | 0.14 |
Sharpe Ratio 12m | -0.09 |
Alpha | 89.13 |
Beta | 0.355 |
Volatility | 11.37% |
Current Volume | 0.1k |
Average Volume 20d | 0k |
Stop Loss | 5.3 (-2.8%) |
What is the price of ABLD shares?
As of July 15, 2025, the stock is trading at EUR 5.45 with a total of 105 shares traded.
Over the past week, the price has changed by +1.87%, over one month by +0.93%, over three months by -0.89% and over the past year by +96.45%.
As of July 15, 2025, the stock is trading at EUR 5.45 with a total of 105 shares traded.
Over the past week, the price has changed by +1.87%, over one month by +0.93%, over three months by -0.89% and over the past year by +96.45%.
Is AbL Diagnostics a good stock to buy?
Neither. Based on ValueRay´s Analyses, AbL Diagnostics is currently (July 2025) neither a good nor a bad stock to buy. It has a ValueRay Growth Rating of 30.02 and therefor a technical neutral rating according to historical growth.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of ABLD is around 5.68 EUR . This means that ABLD is currently overvalued and has a potential downside of 4.22%.
Neither. Based on ValueRay´s Analyses, AbL Diagnostics is currently (July 2025) neither a good nor a bad stock to buy. It has a ValueRay Growth Rating of 30.02 and therefor a technical neutral rating according to historical growth.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of ABLD is around 5.68 EUR . This means that ABLD is currently overvalued and has a potential downside of 4.22%.
Is ABLD a buy, sell or hold?
AbL Diagnostics has no consensus analysts rating.
AbL Diagnostics has no consensus analysts rating.
What are the forecasts for ABLD share price target?
According to our own proprietary Forecast Model, ABLD AbL Diagnostics will be worth about 6.3 in July 2026. The stock is currently trading at 5.45. This means that the stock has a potential upside of +15.23%.
According to our own proprietary Forecast Model, ABLD AbL Diagnostics will be worth about 6.3 in July 2026. The stock is currently trading at 5.45. This means that the stock has a potential upside of +15.23%.
Issuer | Target | Up/Down from current |
---|---|---|
Wallstreet Target Price | 6 | 10.3% |
Analysts Target Price | - | - |
ValueRay Target Price | 6.3 | 15.2% |